Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 11, 2024 7:24pm
103 Views
Post# 35927489

RE:RE:RE:IRENE Study

RE:RE:RE:IRENE StudyMarch 11, 2024 - While many widely available resources for breast cancer patients lump all cases of the disease together, Gilead Sciences is drilling down into the specifics of metastatic breast cancer (MBC) in particular. 

The Expose MBCwebsite went live earlier this month—just in time for Triple-Negative Breast Cancer (TNBC) Awareness Day on March 3—and is a collaborative effort between Gilead and a handful of breast cancer-focused nonprofit organizations: Living Beyond Breast Cancer, Project Life, the Chrysalis Initiative and the Young Survival Coalition.


The new campaign leans into the theme of revealing often-unsaid truths about MBC, repeating the phrase “It’s Time”—to “get real” about the disease, to “let the fear and isolation melt away” and to “expose metastatic breast cancer”—in between clips of patients sharing their experiences of living with MBC.

https://www.fiercepharma.com/marketing/gilead-launches-patient-hub-expose-realities-living-metastatic-breast-cancer
<< Previous
Bullboard Posts
Next >>